tiprankstipranks
Trending News
More News >
Ovid Therapeutics Inc (OVID)
NASDAQ:OVID

Ovid Therapeutics (OVID) Stock Statistics & Valuation Metrics

Compare
1,416 Followers

Total Valuation

Ovid Therapeutics has a market cap or net worth of $24.06M. The enterprise value is $120.85M.
Market Cap$24.06M
Enterprise Value$120.85M

Share Statistics

Ovid Therapeutics has 71,109,510 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding71,109,510
Owned by Insiders5.36%
Owned by Institutions39.48%

Financial Efficiency

Ovid Therapeutics’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -74.58%.
Return on Equity (ROE)-0.39
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-74.58%
Return on Capital Employed (ROCE)-0.76
Revenue Per Employee24.61K
Profits Per Employee-1.15M
Employee Count23
Asset Turnover<0.01
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Ovid Therapeutics is -2.50. Ovid Therapeutics’s PEG ratio is 0.02.
PE Ratio-2.50
PS Ratio0.00
PB Ratio0.99
Price to Fair Value0.97
Price to FCF-2.31
Price to Operating Cash Flow-2.37
PEG Ratio0.02

Income Statement

In the last 12 months, Ovid Therapeutics had revenue of 566.00K and earned -26.43M in profits. Earnings per share was -0.37.
Revenue566.00K
Gross Profit566.00K
Operating Income-61.88M
Pretax Income-26.43M
Net Income-26.43M
EBITDA-61.27M
Earnings Per Share (EPS)-0.37

Cash Flow

In the last 12 months, operating cash flow was -49.55M and capital expenditures -52.00K, giving a free cash flow of -49.58M billion.
Operating Cash Flow-49.55M
Free Cash Flow-49.58M
Free Cash Flow per Share-0.70

Dividends & Yields

Ovid Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.83
52-Week Price Change-59.52%
50-Day Moving Average0.31
200-Day Moving Average0.70
Relative Strength Index (RSI)57.69
Average Volume (3m)1.32M

Important Dates

Ovid Therapeutics upcoming earnings date is Aug 18, 2025, TBA (Confirmed).
Last Earnings DateMay 13, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date

Financial Position

Ovid Therapeutics as a current ratio of 5.32, with Debt / Equity ratio of 12.50%
Current Ratio5.32
Quick Ratio5.32
Debt to Market Cap0.00
Net Debt to EBITDA0.19
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Ovid Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Ovid Therapeutics EV to EBITDA ratio is -0.89, with an EV/FCF ratio of -0.98.
EV to Sales96.57
EV to EBITDA-0.89
EV to Free Cash Flow-0.98
EV to Operating Cash Flow-0.98

Balance Sheet

Ovid Therapeutics has $43.00M in cash and marketable securities with $14.43M in debt, giving a net cash position of -$28.57M billion.
Cash & Marketable Securities$43.00M
Total Debt$14.43M
Net Cash-$28.57M
Net Cash Per Share-$0.40
Tangible Book Value Per Share$0.96

Margins

Gross margin is 8.06%, with operating margin of -10933.75%, and net profit margin of -4670.14%.
Gross Margin8.06%
Operating Margin-10933.75%
Pretax Margin-4670.14%
Net Profit Margin-4670.14%
EBITDA Margin-10825.27%
EBIT Margin-10933.57%

Analyst Forecast

The average price target for Ovid Therapeutics is $2.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$2.83
Price Target Upside732.35% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast15.73%
EPS Growth Forecast51.00%

Scores

Smart Score6
AI Score50.9
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis